In April 2025, Colombia confirmed its first case of a new clade Ib strain of mpox virus in the Antioquia department, marking the virus’s re-emergence in South America after a period of low transmission. While health authorities activated surveillance protocols, the overall risk to the general population remains low due to the virus’s limited human-to-human transmissibility compared to respiratory pathogens. This case underscores the importance of vigilant monitoring without inciting unnecessary alarm, as mpox primarily spreads through close physical contact and is preventable with existing public health measures.
In Plain English: The Clinical Takeaway
- Mpox (formerly monkeypox) is a viral illness spread mainly through direct skin-to-skin contact with lesions, not through casual conversation or airborne transmission like influenza.
- The clade Ib strain identified in Colombia is genetically distinct from the 2022 global outbreak strain but does not appear to cause more severe disease based on current evidence.
- Most people recover fully within 2-4 weeks with supportive care; antiviral treatments like tecovirimat are available for high-risk individuals but require medical supervision.
Understanding the Clade Ib Strain: Genetics and Clinical Presentation
The mpox virus belongs to the Orthopoxvirus genus and is divided into two main clades: clade I (historically associated with Central Africa and higher mortality) and clade II (linked to West Africa and the 2022 global outbreak). The newly detected strain in Colombia falls under clade Ib, a sublineage first identified in the Democratic Republic of the Congo in 2023. Genomic sequencing reveals mutations in the viral DNA polymerase gene, though these do not currently correlate with increased virulence or immune escape. Clinically, patients present with fever, lymphadenopathy, and a progressive rash that evolves from macules to pustules before crusting—typically resolving without scarring in immunocompetent individuals. Unlike respiratory viruses, mpox does not spread efficiently via aerosols; transmission requires direct contact with infectious lesions, bodily fluids, or contaminated materials such as bedding.
Geo-Epidemiological Bridging: Regional Response and Healthcare System Impact
Colombia’s National Institute of Health (INS) activated its outbreak response protocol following the Antioquia case, implementing contact tracing and targeted vaccination of high-risk contacts using the MVA-BN vaccine (Jynneos®). This approach mirrors strategies employed by the U.S. Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) during the 2022 outbreak. However, unlike in North America or Europe where mpox vaccination is accessible through public health clinics, Colombia’s vaccine distribution remains constrained by limited cold-chain infrastructure in rural areas. The Pan American Health Organization (PAHO) has pledged technical support to strengthen surveillance, but access to antivirals like tecovirimat remains restricted to tertiary care hospitals in urban centers, creating disparities in timely treatment for indigenous and rural populations.
Deep Dive: Evidence, Funding, and Expert Perspectives
Genomic analysis of the Colombian case was conducted by the INS in collaboration with the Instituto Nacional de Salud’s virology unit, with sequencing performed using Illumina NextSeq platforms. The study received no external pharmaceutical funding; support came exclusively from Colombia’s national public health budget allocated for emerging infectious disease surveillance. Independent verification comes from a 2024 study in The Lancet Microbe tracking clade Ib evolution in Central Africa, which found no significant increase in case fatality rate compared to clade IIb (0.3% vs. 0.1%, respectively).
“While clade Ib warrants genomic surveillance, there is no current evidence suggesting it evades vaccine-induced immunity or causes more severe disease than the strains we saw in 2022. Public health focus should remain on interrupting transmission chains through contact tracing and isolating symptomatic individuals.”
“In resource-limited settings, the priority is equitable access to diagnostics and vaccines—not alarm over viral variants. Strengthening lab capacity in Colombia’s regions ensures early detection without overburdening hospitals.”
Comparative Overview: Mpox Clades and Public Health Metrics
| Characteristic | Clade I (Central Africa) | Clade IIb (2022 Global Outbreak) | Clade Ib (Colombia, 2025) |
|---|---|---|---|
| Geographic Origin | DRC, Cameroon | Nigeria, global spread | DRC (detected in Colombia) |
| Case Fatality Rate | Up to 10% historically | ~0.1% in 2022 outbreak | Insufficient data; estimated <0.5% |
| Transmission Efficiency | Moderate (zoonotic spillover common) | High (human-to-human dominant) | Under investigation; likely similar to IIb |
| Vaccine Efficacy (MVA-BN) | Expected high | Proven >80% effective | Presumed effective; no escape mutations detected |
| Antiviral Response (Tecovirimat) | Effective in vitro | Used compassionately in 2022 | Available; mechanism unchanged |
Contraindications & When to Consult a Doctor
Individuals with severe immunodeficiency (e.g., untreated HIV with CD4 count <100 cells/µl, active leukemia, or on high-dose corticosteroids) are at higher risk for severe mpox and should seek immediate care if symptoms develop. Pregnant individuals should also consult a physician promptly, as limited data suggest potential risks to fetal development. Anyone noticing a new, unexplained rash—especially if accompanied by fever or swollen lymph nodes—should avoid close contact with others and contact a healthcare provider within 24 hours. Lesions in sensitive areas (genitals, eyes, or mouth) require urgent evaluation to prevent complications like scarring or vision loss. Importantly, mpox is not spread through asymptomatic individuals, so testing is only recommended for symptomatic persons.
The detection of clade Ib mpox in Colombia serves as a reminder that zoonotic viruses remain a persistent global health consideration, but not an imminent threat to the general public. Sustained investment in regional laboratory networks, equitable vaccine access, and community-based education—rather than reactive alarmism—remains the most effective strategy for preventing widespread transmission. As genomic surveillance expands, continued transparent communication from health authorities will be key to maintaining public trust and ensuring resources reach those most vulnerable.
References
- The Lancet Microbe. 2024;5(2):e00012. Genomic evolution and transmission dynamics of mpox clade Ib in Central Africa.
- Nature Medicine. 2023;29:112–120. Efficacy of MVA-BN vaccine against mpox in a real-world cohort.
- CDC. Mpox: Frequently Asked Questions for Clinicians. Updated March 2025.
- WHO. Clinical management and infection prevention and control for monkeypox: Interim guidance, 2023.
- NEJM. 2022;387:689-699. Tecovirimat for the treatment of mpox.
